http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110283161-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2016-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110283161-B |
| titleOfInvention | Crystallization of Pyridine-Substituted 2-Aminopyridine Protein Kinase Inhibitors |
| abstract | The invention discloses the crystallization of pyridine-substituted 2-aminopyridine protein kinase inhibitors, in particular to 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4 Citrate crystal of '-methoxy-6'-((S)-2-methylpiperazine-1-yl)-3,3'-bipyridyl-6-amine, its preparation method, and crystalline composition and pharmaceutical compositions, and also discloses the use of citrate crystals of the compound of formula I and diseases related to protein kinases, and the citrate crystals of the present invention have at least the following aspects: On the one hand, it is better than 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4'-methoxy-6'-((S)-2-methyl piperazin-1-yl)-3,3'-bipyridyl-6-amine or 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4 Other salts of '-methoxy-6'-((S)-2-methylpiperazine-1-yl)-3,3'-bipyridyl-6-amine. |
| priorityDate | 2015-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 149.